Annovis Bio, Inc. (ANVS) is a clinical-stage biopharmaceutical company that is driving significant advancements in the arena of neuroscience with their transformative approaches to neurodegenerative diseases. The company is publicly traded on the NYSE American stock exchange under the symbol ANVS.
Founded by Maria Maccecchini in 2008, Annovis Bio is headquartered in Berwyn, Pennsylvania. The company was established with the main aim to address the urgent need for effective treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. These diseases affect millions of people worldwide and cause untold suffering to patients and their families. Annovis Bio's mission is to change this narrative through its innovative science and therapies.
This company is unique due to the dual-focus on both Alzheimer's and Parkinson's disease, which has placed it in a very promising position in the biotech sector. The company's leading drug candidate, ANVS401, intends to alleviate many debilitating symptoms associated with these diseases by blocking multiple neurotoxic proteins, a mechanism that could potentially treat a broad spectrum of neurodegenerative disorders.
Besides the core focus on Alzheimer's and Parkinson's, Annovis Bio also seeks to develop treatments for other diseases such as Down syndrome, and other less-common neurodegenerative disorders like Amyotrophic lateral sclerosis (ALS) and Huntington's disease.
Annovis Bio has quickly distinguished themselves in the field by demonstrating promising results in human trials. The ground-breaking approach utilizes proprietary compounds that have been scientifically proven to not only stop, but also reverse, nerve cell deficits.
On the financial side, Annovis Bio has seen consistent growth in its stock market performance, which is testament to the confidence from investors in their novel approach to treating neurodegenerative diseases.
From a business perspective, Annovis Bio has secured partnerships not only in the medical research field but also within the pharmaceutical industry. By leveraging such partnerships, the company has been able to further its research and accelerate its processes towards delivering promising solutions.
In conclusion, Annovis Bio has steadily carved a niche for itself with its innovative approach to treating neurodegenerative diseases. With their pioneering research and therapies, they are a beacon of hope for patients across the globe inflicted by such diseases. It's safe to say that Annovis Bio's work could prove to be a turning point in medicine, resulting in significantly improved quality of life for millions of people.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Annovis Bio has exceeded its enrollment goal for the pivotal Phase 3 trial of its Alzheimer's drug, buntanetap, recruiting 850 patients against a target of 760. This success is significant given the strict entry criteria and the challenge of trial recruitment in drug development. The company is also progressing with a separate Parkinson's trial for the same drug, with topline data for the Alzheimer's study expected in early 2027.
Annovis Bio, Inc. will host a corporate update webinar on September 2, 2026, at 4:00 p.m. EDT to discuss its recent progress, ongoing clinical programs, and upcoming milestones for its investigational oral therapy, buntanetap, for neurodegenerative diseases. Key updates include the full enrollment of its pivotal Phase 3 Alzheimer's disease trial, preparations for data readout and regulatory submissions in 2027, and advancements in its Parkinson's disease program. Maria Maccecchini, Ph.D., Founder, President, and CEO, will present the updates.